Does the media favor CLDX or HALO?

In the previous week, Halozyme Therapeutics had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 19 mentions for Halozyme Therapeutics and 17 mentions for Celldex Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.10 beat Celldex Therapeutics' score of 0.74 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 13 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CLDX or IONS?

In the previous week, Ionis Pharmaceuticals had 9 more articles in the media than Celldex Therapeutics. MarketBeat recorded 26 mentions for Ionis Pharmaceuticals and 17 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.74 beat Ionis Pharmaceuticals' score of 0.69 indicating that Celldex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 11 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CLDX or ALKS?

In the previous week, Alkermes had 15 more articles in the media than Celldex Therapeutics. MarketBeat recorded 32 mentions for Alkermes and 17 mentions for Celldex Therapeutics. Alkermes' average media sentiment score of 1.12 beat Celldex Therapeutics' score of 0.74 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 16 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, CLDX or RGEN?

Repligen has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celldex Therapeutics $865K 3,395.57 -$258.76M -$4.26 N/A Repligen $738.26M 10.75 $48.89M $0.90 156.35

Does the media favor CLDX or RGEN?

In the previous week, Repligen had 24 more articles in the media than Celldex Therapeutics. MarketBeat recorded 41 mentions for Repligen and 17 mentions for Celldex Therapeutics. Repligen's average media sentiment score of 1.01 beat Celldex Therapeutics' score of 0.74 indicating that Repligen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 22 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CLDX or LGND?

In the previous week, Celldex Therapeutics had 4 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 17 mentions for Celldex Therapeutics and 13 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.14 beat Celldex Therapeutics' score of 0.74 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Celldex Therapeutics (CLDX) Competitors

$37.42 -1.07 (-2.78%)

As of 11:45 AM Eastern

Compare

CLDX vs. HALO, IONS, ALKS, RGEN, and LGND

Should you buy Celldex Therapeutics stock or one of its competitors? MarketBeat compares Celldex Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Celldex Therapeutics include Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Repligen (RGEN), and Ligand Pharmaceuticals (LGND). These companies are all part of the "biotechnology" industry.

How does Celldex Therapeutics compare to Halozyme Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Halozyme Therapeutics (NASDAQ:HALO) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

Halozyme Therapeutics has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$865K	3,395.57	-$258.76M	-$4.26	N/A
Halozyme Therapeutics	$1.40B	6.99	$316.89M	$2.78	29.60

Halozyme Therapeutics has a net margin of 23.13% compared to Celldex Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 187.91% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
Halozyme Therapeutics	23.13%	187.91%	21.92%

Celldex Therapeutics presently has a consensus target price of $54.62, suggesting a potential upside of 45.95%. Halozyme Therapeutics has a consensus target price of $81.60, suggesting a potential downside of 0.84%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Celldex Therapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54

97.8% of Halozyme Therapeutics shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Celldex Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

In the previous week, Halozyme Therapeutics had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 19 mentions for Halozyme Therapeutics and 17 mentions for Celldex Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.10 beat Celldex Therapeutics' score of 0.74 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	13 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Halozyme Therapeutics beats Celldex Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Celldex Therapeutics compare to Ionis Pharmaceuticals?

Celldex Therapeutics (NASDAQ:CLDX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Celldex Therapeutics has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -64.76%. Celldex Therapeutics' return on equity of -50.72% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
Ionis Pharmaceuticals	-64.76%	-106.23%	-16.97%

Celldex Therapeutics presently has a consensus target price of $54.62, suggesting a potential upside of 45.95%. Ionis Pharmaceuticals has a consensus target price of $94.85, suggesting a potential upside of 84.25%. Given Ionis Pharmaceuticals' higher probable upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Ionis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.77

In the previous week, Ionis Pharmaceuticals had 9 more articles in the media than Celldex Therapeutics. MarketBeat recorded 26 mentions for Ionis Pharmaceuticals and 17 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.74 beat Ionis Pharmaceuticals' score of 0.69 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	11 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Celldex Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market.

Celldex Therapeutics has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$865K	3,395.57	-$258.76M	-$4.26	N/A
Ionis Pharmaceuticals	$944M	9.01	-$381.39M	-$2.07	N/A

Summary

Celldex Therapeutics beats Ionis Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Celldex Therapeutics compare to Alkermes?

Celldex Therapeutics (NASDAQ:CLDX) and Alkermes (NASDAQ:ALKS) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

In the previous week, Alkermes had 15 more articles in the media than Celldex Therapeutics. MarketBeat recorded 32 mentions for Alkermes and 17 mentions for Celldex Therapeutics. Alkermes' average media sentiment score of 1.12 beat Celldex Therapeutics' score of 0.74 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	16 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alkermes has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$865K	3,395.57	-$258.76M	-$4.26	N/A
Alkermes	$1.48B	5.53	$241.66M	$0.90	54.01

Celldex Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

95.2% of Alkermes shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by company insiders. Comparatively, 4.6% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Celldex Therapeutics presently has a consensus target price of $54.62, suggesting a potential upside of 45.95%. Alkermes has a consensus target price of $54.56, suggesting a potential upside of 12.25%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Celldex Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

Alkermes has a net margin of 3.96% compared to Celldex Therapeutics' net margin of 0.00%. Alkermes' return on equity of 4.15% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
Alkermes	3.96%	4.15%	2.19%

Summary

Alkermes beats Celldex Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Celldex Therapeutics compare to Repligen?

Celldex Therapeutics (NASDAQ:CLDX) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Celldex Therapeutics currently has a consensus target price of $54.62, indicating a potential upside of 45.95%. Repligen has a consensus target price of $166.43, indicating a potential upside of 18.27%. Given Celldex Therapeutics' higher possible upside, analysts clearly believe Celldex Therapeutics is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Repligen	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.88

Repligen has a net margin of 5.29% compared to Celldex Therapeutics' net margin of 0.00%. Repligen's return on equity of 5.30% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
Repligen	5.29%	5.30%	3.79%

97.6% of Repligen shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 0.6% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Celldex Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Repligen has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Repligen has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$865K	3,395.57	-$258.76M	-$4.26	N/A
Repligen	$738.26M	10.75	$48.89M	$0.90	156.35

In the previous week, Repligen had 24 more articles in the media than Celldex Therapeutics. MarketBeat recorded 41 mentions for Repligen and 17 mentions for Celldex Therapeutics. Repligen's average media sentiment score of 1.01 beat Celldex Therapeutics' score of 0.74 indicating that Repligen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	22 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Repligen beats Celldex Therapeutics on 14 of the 17 factors compared between the two stocks.

How does Celldex Therapeutics compare to Ligand Pharmaceuticals?

Celldex Therapeutics (NASDAQ:CLDX) and Ligand Pharmaceuticals (NASDAQ:LGND) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Ligand Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$865K	3,395.57	-$258.76M	-$4.26	N/A
Ligand Pharmaceuticals	$268.09M	21.70	$124.45M	$7.37	39.40

Ligand Pharmaceuticals has a net margin of 55.95% compared to Celldex Therapeutics' net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 16.19% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Celldex Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

Celldex Therapeutics presently has a consensus price target of $54.62, indicating a potential upside of 45.95%. Ligand Pharmaceuticals has a consensus price target of $319.00, indicating a potential upside of 9.86%. Given Celldex Therapeutics' higher possible upside, equities analysts plainly believe Celldex Therapeutics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, Celldex Therapeutics had 4 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 17 mentions for Celldex Therapeutics and 13 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.14 beat Celldex Therapeutics' score of 0.74 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ligand Pharmaceuticals beats Celldex Therapeutics on 12 of the 17 factors compared between the two stocks.

Get Celldex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLDX vs. The Competition

Export

Metric	Celldex Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.93B	$3.65B	$6.86B	$12.37B
Dividend Yield	N/A	2.13%	2.65%	10.11%
P/E Ratio	-8.77	23.06	27.45	23.66
Price / Sales	3,395.57	212.49	495.52	78.38
Price / Cash	N/A	165.25	51.74	58.30
Price / Book	4.72	7.92	9.91	5.85
Net Income	-$258.76M	$23.81M	$3.61B	$336.64M
7 Day Performance	6.07%	-1.14%	-0.29%	0.02%
1 Month Performance	0.56%	-7.49%	-3.96%	-5.24%
1 Year Performance	70.25%	39.62%	22.83%	17.56%

Celldex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLDX Celldex Therapeutics	2.8668 of 5 stars	$37.42 -2.8%	$54.62 +46.0%	+68.7%	$2.93B	$865K	N/A	150	Upcoming Earnings Analyst Forecast
HALO Halozyme Therapeutics	3.3803 of 5 stars	$83.15 +2.0%	$81.60 -1.9%	+38.6%	$9.76B	$1.40B	29.60	390	Positive News Upcoming Earnings
IONS Ionis Pharmaceuticals	3.6313 of 5 stars	$56.04 +0.1%	$95.90 +71.1%	+22.8%	$9.30B	$944M	N/A	1,402	Analyst Forecast
ALKS Alkermes	3.0385 of 5 stars	$51.57 -2.2%	$52.50 +1.8%	+79.1%	$8.45B	$1.48B	56.30	2,050	Positive News Analyst Forecast
RGEN Repligen	3.894 of 5 stars	$140.03 +6.8%	$165.36 +18.1%	+16.9%	$7.79B	$738.26M	153.45	2,000	Positive News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLDX) was last updated on 7/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celldex Therapeutics (CLDX) Competitors

CLDX vs. HALO, IONS, ALKS, RGEN, and LGND

How does Celldex Therapeutics compare to Halozyme Therapeutics?

Summary

How does Celldex Therapeutics compare to Ionis Pharmaceuticals?

Summary

How does Celldex Therapeutics compare to Alkermes?

Summary

How does Celldex Therapeutics compare to Repligen?

Summary

How does Celldex Therapeutics compare to Ligand Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX vs. The Competition

Celldex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celldex Therapeutics (CLDX) Competitors

CLDX vs. HALO, IONS, ALKS, RGEN, and LGND

How does Celldex Therapeutics compare to Halozyme Therapeutics?

Which has higher earnings & valuation, CLDX or HALO?

Is CLDX or HALO more profitable?

Do analysts rate CLDX or HALO?

Do insiders and institutionals hold more shares of CLDX or HALO?

Which has more risk & volatility, CLDX or HALO?

Does the media favor CLDX or HALO?

Summary

How does Celldex Therapeutics compare to Ionis Pharmaceuticals?

Is CLDX or IONS more profitable?

Do analysts rate CLDX or IONS?

Does the media refer more to CLDX or IONS?

Do insiders and institutionals hold more shares of CLDX or IONS?

Which has more risk & volatility, CLDX or IONS?

Which has better earnings & valuation, CLDX or IONS?

Summary

How does Celldex Therapeutics compare to Alkermes?

Does the media favor CLDX or ALKS?

Which has higher valuation & earnings, CLDX or ALKS?

Which has more volatility and risk, CLDX or ALKS?

Do insiders and institutionals have more ownership in CLDX or ALKS?

Do analysts recommend CLDX or ALKS?

Is CLDX or ALKS more profitable?

Summary

How does Celldex Therapeutics compare to Repligen?

Do analysts recommend CLDX or RGEN?

Is CLDX or RGEN more profitable?

Do insiders & institutionals believe in CLDX or RGEN?

Which has more volatility & risk, CLDX or RGEN?

Which has stronger valuation & earnings, CLDX or RGEN?

Does the media favor CLDX or RGEN?

Summary

How does Celldex Therapeutics compare to Ligand Pharmaceuticals?

Which has better earnings and valuation, CLDX or LGND?

Is CLDX or LGND more profitable?

Do insiders and institutionals believe in CLDX or LGND?

Which has more risk and volatility, CLDX or LGND?

Do analysts recommend CLDX or LGND?

Does the media favor CLDX or LGND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX vs. The Competition

Celldex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools